Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.
Minecraft master Craftee experiences a world that becomes increasingly realistic with every interaction. Dua Lipa songwriter stabbed to death UK hot weather maps show 9-day heatwave as 30C to roast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results